Thrombotic Microangiopathies clinical trials at UC Health
2 research studies open to eligible people
open to eligible people ages up to 30 years
Thrombotic microangiopathy (TMA) is a common complication in the stem cell transplant population. Certain populations within the hematopoietic stem cell transplant (HSCT) population are at a higher risk than others. Defibrotide is an endothelial stabilizing agent which may prevent the endothelial damage that triggers TMA in HSCT patients. The feasibility, safety, and efficacy of defibrotide prophylaxis in a pediatric transplant population is unknown. Twenty five patients age 0 to 30 years receiving autologous or allogeneic hematopoeitic stem cell transplant who meet TMA high risk criteria will be enrolled. Patients will receive Defibrotide for 28-35 days starting before conditioning, and will be closely monitored for any adverse events up through 6 months post-transplant. The feasibility of administering defibrotide will be evaluated as well as incidence of TMA.
open to eligible people ages 18 years and up
The purpose of this study is to assess the safety, tolerability, and clinical activity of OMS721 in subjects with thrombotic microangiopathies (TMA), which include atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenia (TTP), and hematopoietic stem cell transplant -associated TMA (HSCT-associated TMA). The study will also evaluate clinical activity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response (ADA).